Asset profile
HDM1005
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-03.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 11 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HDM1005: this drug | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| HS-20094 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| KP405 | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
February 2027 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.